In gliomas, the use of common PD-1 inhibitors, such as nivolumab and pembrolizumab, faces several challenges, including the limitations of the BBB and the complexity of tumor immune evasion mechanisms. The gene discussed is PDCD1; the disease is central nervous system cancer.